✨ Free AI Report
EyePoint, Inc. (formerly EyePoint Pharmaceuticals): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research EyePoint, Inc. (formerly EyePoint Pharmaceuticals)
Company Research

EyePoint, Inc. (formerly EyePoint Pharmaceuticals): Business Overview, Financials & Competitive Analysis

EyePoint, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company developing innovative sustained intraocular drug delivery therapies for serious retinal diseases. The company focuses on wet AMD, diabetic ma...

Analyst-debate audio for EyePoint, Inc. (formerly EyePoint Pharmaceuticals)

AskCyborg analysts argue the bull and bear cases for EyePoint, Inc. (formerly EyePoint Pharmaceuticals) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

EyePoint offers compelling upside if DURAVYU succeeds in Phase 3 trials, but investors face binary regulatory and clinical risk...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals/Ophthalmology - Retinal Disease Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest EyePoint, Inc. (formerly EyePoint Pharmaceuticals) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

EyePoint, Inc. (formerly EyePoint Pharmaceuticals) Overview

Pro stress-test →

EyePoint, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company developing innovative sustained intraocular drug delivery therapies for serious retinal diseases. The company focuses on wet AMD, diabetic macular edema, and non-proliferative diabetic retinopathy using its proprietary Durasert E bioerodible platform technology, which has safely been administered to thousands of patients across four FDA-approved products.

Strategic Profile

Pro stress-test →

EyePoint is strategically positioned as a pure-play retinal disease specialist, leveraging three decades of validated drug delivery experience. The company has transitioned from a diversified pharma portfolio to a focused clinical-stage competitor by exiting its specialty pharma business, allowing concentrated resources for DURAVYU, its lead investigational product combining a patent-protected tyrosine kinase inhibitor with Durasert E technology.

Competitive Landscape

Pro stress-test →

EyePoint competes in the wet AMD and diabetic retinal disease treatment market against established antiVEGF therapies (Avastin, Eylea, Beovu) and emerging sustained-delivery competitors. Key differentiation lies in Durasert E's claimed durability and patient convenience advantages, positioning DURAVYU as a next-generation option if clinical efficacy validates superiority. The retinal disease market is consolidating with biosimilars and new mechanisms of action intensifying competition.

Industry Context

EyePoint, Inc. (formerly EyePoint Pharmaceuticals) operates in Biopharmaceuticals/Ophthalmology - Retinal Disease Therapeutics.

Key facts

Founded: 1987 · Headquarters: Watertown, Massachusetts, US · Employees: 165 · Revenue: $43.3M (2024) · Market cap: $1.2B

What the analysts stress-tested

The top findings that survived the multi-agent debate for EyePoint, Inc. (formerly EyePoint Pharmaceuticals).

  • Company underwent strategic name change (December 2025) and business model shift, consolidating focus on retinal diseases after exiting specialty pharma
  • DURAVYU Phase 3 progress is main value driver; FDA conditionally accepted proprietary name in February 2025
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Company changed name from EyePoint Pharmaceuticals, Inc. to EyePoint, Inc.
  • February 2025FDA conditionally accepted DURAVYU as proprietary name for EYP-1901
  • +2 moreTrack every material event for EyePoint, Inc. (formerly EyePoint Pharmaceuticals) as it happens. Explore monitoring →
Get alerted when EyePoint, Inc. (formerly EyePoint Pharmaceuticals) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Eylea (aflibercept)Dominant monthly antiVEGF injection standard for wet AMD and DME→Beovu (brolucizumab)Newer antiVEGF with 12-week dosing for wet AMD→Avastin (bevacizumab)Off-label antiVEGF used for retinal diseases with frequent dosing→

Compare EyePoint, Inc. (formerly EyePoint Pharmaceuticals) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

EyePoint, Inc. (formerly EyePoint Pharmaceuticals) operates in Biopharmaceuticals/Ophthalmology - Retinal Disease Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals/Ophthalmology - Retinal Disease Therapeutics research →
NEW · MCP server

Ask your AI assistant about EyePoint, Inc. (formerly EyePoint Pharmaceuticals)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare EyePoint, Inc. (formerly EyePoint Pharmaceuticals) and its top competitor on Cyborg Score”
“What did EyePoint, Inc. (formerly EyePoint Pharmaceuticals) do this quarter?”
“Is EyePoint, Inc. (formerly EyePoint Pharmaceuticals) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does EyePoint, Inc. (formerly EyePoint Pharmaceuticals) do?+
EyePoint, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company developing innovative sustained intraocular drug delivery therapies for serious retinal diseases. The company focuses on wet AMD, diabetic ma...
What is EyePoint, Inc. (formerly EyePoint Pharmaceuticals)'s Cyborg Score?+
EyePoint, Inc. (formerly EyePoint Pharmaceuticals) has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are EyePoint, Inc. (formerly EyePoint Pharmaceuticals)'s main competitors?+
Named competitors include Eylea (aflibercept), Beovu (brolucizumab), Avastin (bevacizumab). The full competitive landscape is in the AskCyborg report.
How can I get the full EyePoint, Inc. (formerly EyePoint Pharmaceuticals) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the EyePoint, Inc. (formerly EyePoint Pharmaceuticals) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track EyePoint, Inc. (formerly EyePoint Pharmaceuticals) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Innovent Biologics, Inc.Top companies in Biopharmaceuticals by Cyborg Score